Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/149599| Author(s): | Garrido, MM Ribeiro, RM Krüger, K Pinheiro, LC Guimarães, JT Holdenrieder, S |
| Title: | Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis |
| Publisher: | International Institute of Anticancer Research |
| Issue Date: | 2021 |
| Abstract: | Background/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. Patients and Methods: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. Results: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). Conclusion: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls. |
| Subject: | Prostate cancer circulating nucleosomes cell death detection ELISA immunogenic cell death markers sRAGE HMGB1 |
| DOI: | 10.21873/invivo.12492 |
| URI: | https://hdl.handle.net/10216/149599 |
| Source: | In Vivo. 2021 Jul-Aug;35(4):2207-2212 |
| Document Type: | Artigo em Revista Científica Internacional |
| Rights: | openAccess |
| License: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Appears in Collections: | ISPUP - Artigo em Revista Científica Internacional |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| garrido-ribeiro-iv-2021.pdf | 121.68 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
